トジナメラン Pfizer-BioNTech vaccine BNT162b2

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults.
 Mulligan MJ, et al.〔Nature. 2020 Oct;586(7830):589-593〕（査読済み）


Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
 Walsh EE, et al.〔N Engl J Med. 2020 Dec 17;383(25):2439-2450〕（査読済み）


Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
 Polack FP, et al.〔N Engl J Med. 2020 Dec 31;383(27):2603-2615〕（査読済み）


BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
 Sahin U, et al.〔medRxiv. 2020 Dec 11〕（査読前）


Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
 Muik A, et al.〔Science. 2021 Jan 29:eabg6105〕（査読済み）


The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence
 Chodick G, et al.〔medRxiv. 2021 Jan 29〕（査読前）


Decreased SARS-CoV-2 viral load following vaccination
 Levine-Tiefenbrun M, et al.〔medRxiv. 2021 Feb 08〕（査読前）


Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021
 Abu Jabal K, et al.〔Euro Surveill. 2021 Feb;26(6)〕（査読済み）


Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine
 Krammer F, et al.〔medRxiv. 2021 Feb 01〕（査読前）


Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1
 Stamatatos L, et al.〔medRxiv. 2021 Feb. 08〕（査読前）